Clin Infect Dis by Halpin, Alison Laufer & McDonald, L. Clifford
The Dawning of Microbiome Remediation for Addressing 
Antibiotic Resistance
Alison Laufer Halpin, PhD and L. Clifford McDonald, MD
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention
The Centers for Disease Control and Prevention estimates that over two million infections in 
the United States each year are caused by antibiotic-resistant pathogens described as urgent, 
serious, and concerning threats, leading to 23,000 deaths and billions of dollars in excess 
medical costs [1]. Nearly half of these 18 antibiotic resistant threats are health care-
associated pathogens and at least five frequently colonize the lower intestinal microbiota of 
patients. Among the many host and environmental factors that influence the composition of 
our microbiota, the most significant is the receipt of antibiotics [2–4]. Treatment with 
antibiotics eliminates not only pathogenic but also beneficial bacteria, resulting in severe 
disruption of the intestinal microbiota for an extended period of time (>6 months) [2]. This 
loss of diversity in the intestinal microbial composition places individuals at increased risk 
for poor outcomes, including colonization by pathogens, such as C. difficile and other 
multidrug-resistant organisms (MDROs), which can give way to their expansion, dominance, 
and infection and bacteremia [5–8].
Among the almost 500,000 cases of Clostridium difficile infection (CDI) that occur each 
year, there are an estimated 83,000 recurrences of infection annually [9]. In recent years, the 
use of fecal microbiota transplantation (FMT) has garnered attention as a method for treating 
recurrent CDI by restoring the intestinal microbiota to a healthy state, preventing further 
recurrences [10]. The FDA has determined that FMTs are a biological product and a drug, 
and an investigational new drug (IND) application is required to use FMT for clinical 
indications, except for recurrent CDI for which an application is encouraged, but not 
required (http://www.regulations.gov/#!documentDetail;D=FDA-2013-D-0811-0002). This 
leaves a window open to use FMT for eradication of other MDROs, provided an IND 
application is submitted. Efforts to treat recurrent CDI have found concomitant eradication 
of other MDROs [11] and other groups have demonstrated clearance of ongoing colonization 
or recurrent infection by MDROs through FMT [12, 13].
In this issue of Clinical Infectious Diseases, Millan et al. report on a small study (N=20) of 
patients who underwent FMT via colonoscopy for recurrent CDI. The investigators 
demonstrated, using a combination of deep sequencing metagenomics and resistance gene 
microarray, a reduction in the diversity and number of resistance genes in patients’ 
microbiota (i.e., resistome) following FMT. Although this was a small, uncontrolled study, 
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there was additional indirect evidence for a causal role for FMT in shrinking the resistome 
found in the 9 of 20 patients who failed their initial FMT, requiring a second FMT. This 
clinical failure correlated with a failure to reduce the resistome, along with a failure to 
increase bacterial diversity (i.e., resistance gene diversity varied inversely with bacterial 
diversity) and a persistent dominance by Proteobacteria, especially Escherichia coli and 
Klebsiella pneumoniae. In addition, the investigators demonstrated that the microbiomes of 
the 3 FMT donors were similar in diversity to a healthy cohort (age 18–40 years) from the 
Human Microbiome Project.
Nonetheless, the study lacks a recurrent CDI control group that did not receive FMT, and 
therefore one cannot assess how much FMT contributes to shrinkage of the resistome over 
and above simply avoiding subsequent antibiotic exposure. In addition, current 
metagenomics methods are unable to link an antibiotic resistance gene to a particular species 
member of the microbiome and thereby identify potentially pathogenic MDROs present. 
Finally, the load of antibiotic resistance genes present in these patients and correlation of the 
load with risk of developing a subsequent MDRO infection or transmitting MDROs or 
determinants to other patients are unknown.
We can anticipate various routes to the future use of microbiome remediation as a means to 
address antibiotic resistance. While FMT using screened, healthy donors is currently widely 
practiced in the treatment of recurrent CDI, one can foresee a possible day when a patient’s 
own microbiome is electively harvested, frozen or otherwise ‘banked’, and later used for 
autologous re-transplant following a microbiome-disrupting therapy or intervention [14]. 
Examples of this might include intense periods of antibiotic and other microbiome disruptive 
exposures as encountered during organ transplantation, hematopoietic stem cell 
transplantation, or chemotherapy. This of course presupposes that the episode of microbiome 
disruption can be planned for ahead of time and that the patient has a baseline microbiome 
that is rich and diverse with a relatively contracted resistome. While donor FMT remains an 
option for patients whose microbiome is already disrupted, another hope for the future is the 
development of defined, advanced probiotics. The recent report of successful treatment of 
multiply recurrent CDI using a processed preparation (SER-109) of approximately 50 
anaerobic spores derived from human donors is one step along the path toward development 
of such advanced probiotics that are defined and sourced in vitro [15].
To explore how understanding the status of the microbiome can be used to tailor antibiotic 
stewardship and infection control decisions, as well as prepare for future FDA-approved 
methods for microbiome remediation, CDC is working to develop Microbiome Disruption 
Indices (MDIs). The goal is to develop standardized criteria that characterize the major 
human microbiomes (beginning with the large intestine) with regard to their vulnerability to 
MDRO colonization and, once colonized, to MDRO dominance that increases the risk for 
infection or transmission of the MDRO to other patients. In addition, such indices can 
communicate the disruptive potential of various drugs, including antibiotics. Potential MDIs 
include compositional indices of diversity, species richness, the presence or absence of 
protective species and, as demonstrated here by Millan et al., measurement of the resistome. 
In addition, MDIs may include indices of the functional status of the microbiome based 
upon either an inferred metagenomics approach (i.e. predicting major metabolic pathways 
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present) or a more direct metabolomics approach (i.e. direct measurement of metabolites). 
With these indices in use, a patient’s status of disruption could be ascertained, and, as a 
patient reaches a threshold suggesting extreme vulnerability to colonization, special reverse 
isolation precautions could be instituted to prevent the acquisition of new resistance traits 
and MDROs while pre-emptive microbiome restoration is considered to achieve improved 
indices. Once colonization has occurred with an MDRO, specific antibiotics that predictably 
drive such patients to a state of MDRO dominance could be avoided. And finally, if 
microbiome dominance by a specific MDRO becomes detected and the patient is at 
increased risk for transmitting the MDRO to another patient, special isolation precautions 
can be undertaken, along with steps to reduce the dominant strain and restore the 
microbiome to a state of increased diversity and lower antibiotic resistance gene burden. The 
current priority in the development of such MDIs is for natural history studies to understand 
the dynamics of microbiome status throughout and between hospitalizations. Given the 
tremendous burden of diseases like CDI, the growing problem of resistance, and the lack of 
effective therapies for many MDROs, there should be a sense of urgency across all the major 
sectors of academia, industry, and government to further develop and establish the role for 
microbiome remediation in the future of medical care and public health.
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